Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

4587 Background: To assess the relationship between tumor burden and sensitivity to hormonal therapy, we evaluated post-therapy PSA changes in patients in the rising PSA state (Scher et al, Urol 2000) and in patients with clinical metastases: non-castrate disease. The objective was to determine the proportion that achieved an undetectable PSA following treatment. METHODS: We identified 473 patients who experienced a rising PSA following local therapy from two available databases at MSKCC. The first database was a series of 233 patients enrolled on vaccine trials between 1995-200; the second was a series of 2652 patients undergoing prostatectomy at MSKCC from 1996-2002. One hundred forty-one patients were initiated on hormonal therapy with CAB, an antiandrogen alone or a GNRH analogue alone, between 1/93 and 6/03. As their primary therapy, 34 received radiation and 106 received radical prostatectomy. Sixty-eight were in a rising PSA clinical state and 73 had non-castrate metastatic disease. RESULTS: A greater number of patients with a rising PSA only achieved an undetectable PSA compared with metastatic patients (57 vs 38%, p=0.03). Rising PSA only patients: Age, Gleason grade, and doubling time did not predict for an undetectable PSA. Achievement of an undetectable PSA was statistically associated with prior prostatectomy, treatment with a GNRH analogue, a lower pretreatment PSA and a shorter time interval from local therapy (p<0.05). Metastatic patients: Achievement of an undetectable PSA was not associated with prior prostatectomy, treatment with a GNRH or the time interval from local therapy. A lower pretreatment PSA and shorter PSA doubling time were statistically associated with an undetectable PSA (p<0.05). Patients with metastatic disease and a detectable PSA nadir were more likely to exhibit progression of disease on imaging with follow-up (p=0.01). CONCLUSIONS: The rate of achieving an undetectable PSA with hormonal therapy is dependent upon the pretreatment PSA and the presence of metastatic disease. Achievement of an undetectable PSA is associated with a delay of disease progression on imaging in metastatic patients. Support: MSKCC SPORE P50 CA 92629-01; Koch Foundation No significant financial relationships to disclose.


Journal article


J Clin Oncol

Publication Date